A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2
496
about 10 years
18+
18 sites in AZ, CT, DE +10
Why this study is shown
What this study is about
This trial is testing a treatment called epcoritamab, given with other medications, for people with non-Hodgkin lymphoma. The goal of it is to see how safe and well the treatment works, including any side effects that may occur.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CC-99282
- 2.Take Cyclophosphamide
- 3.Take Doxorubicin Hydrochloride [HCl]
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), epcoritamab, ibrutinib, lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), polatuzumab vedotin, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
infusion, oral (Oral Tablet), oral (Oral Capsule), oral
Primary: Number of Participants with Dose-Limiting Toxicities (DLT)
Secondary: Best Overall Response (BOR) per Investigator, Duration of response (DOR) per Investigator, Number of Participants with Progression-free survival (PFS), Overall Survival (OS), Percentage of Participants with Complete Response (CR), Time-to-response (TTR)
Oncology